• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by KORU Medical Systems Inc.

    11/14/24 7:00:30 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care
    Get the next $KRMD alert in real time by email
    SC 13G/A 1 d845615dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

     

    Koru Medical Systems, Inc.

    (Name of Issuer)

    Common Stock, $0.01 par value

    (Title of Class of Securities)

    759910102

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 759910102

     

     1   

     Names of reporting persons

     

     Topline Capital Management, LLC

     2  

     Check the appropriate box if a member of a group (see instructions)

     (a) ☐  (b) ☐

     

     3  

     SEC use only

     

     4  

     Citizenship or place of organization

     

      California

    Number of

    shares

    beneficially 

    owned by

    each

    reporting

    person

    with

       5   

     Sole voting power

     

     4,585,532

       6  

     Shared voting power

     

     0

       7  

     Sole dispositive power

     

     4,585,532

       8  

     Shared dispositive power

     

     0

     9   

     Aggregate amount beneficially owned by each reporting person

     

     4,585,532

    10  

     Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

     ☐

    11  

     Percent of class represented by amount in Row (9)

     

     9.9%

    12  

     Type of reporting person (see instructions)

     

     IA

     

     

    2


    CUSIP No. 759910102

     

     1   

     Names of reporting persons

     

     Collin McBirney

     2  

     Check the appropriate box if a member of a group (see instructions)

     (a) ☐  (b) ☐

     

     3  

     SEC use only

     

     4  

     Citizenship or place of organization

     

     USA

    Number of

    shares

    beneficially 

    owned by

    each

    reporting

    person

    with

       5   

     Sole voting power

     

     0

       6  

     Shared voting power

     

     4,585,532

       7  

     Sole dispositive power

     

     0

       8  

     Shared dispositive power

     

     4,585,532

     9   

     Aggregate amount beneficially owned by each reporting person

     

     4,585,532

    10  

     Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

     ☐

    11  

     Percent of class represented by amount in Row (9)

     

     9.9%

    12  

     Type of reporting person (see instructions)

     

     IN/HC

     

     

    3


    CUSIP No. 759910102

     

     1   

     Names of reporting persons

     

     Topline Capital Partners, LP

     2  

     Check the appropriate box if a member of a group (see instructions)

     (a) ☐  (b) ☐

     

     3  

     SEC use only

     

     4  

     Citizenship or place of organization

     

     Delaware

    Number of

    shares

    beneficially 

    owned by

    each

    reporting

    person

    with

       5   

     Sole voting power

     

     4,585,532

       6  

     Shared voting power

     

     0

       7  

     Sole dispositive power

     

     4,585,532

       8  

     Shared dispositive power

     

     0

     9   

     Aggregate amount beneficially owned by each reporting person

     

     4,585,532

    10  

     Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

     ☐

    11  

     Percent of class represented by amount in Row (9)

     

     9.9%

    12  

     Type of reporting person (see instructions)

     

     PN

     

     

    4


    Item 1

     

      (a)

    Name of Issuer:

    Koru Medical Systems, Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    100 Corporate Drive, Mahwah, NJ 07430

     

    Item 2

     

      (a)

    Name of Persons Filing:

    Topline Capital Management, LLC (“TCM”)

    Collin McBirney

    Topline Capital Partners, LP (“TCP” or the “Fund”)

     

      (b)

    Address of Principal Business Office or, if none, Residence:

    544 Euclid Street, Santa Monica, CA 90402

     

      (c)

    Citizenship:

    Reference is made to Row 4 of pages 2 - 4 of this Schedule 13G (this “Schedule”), which are incorporated by reference herein.

     

      (d)

    Title of Class of Securities:

    Common Stock, $0.01 par value

     

      (e)

    CUSIP Number: 759910102

     

    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership

    Reference is hereby made to Rows 5-9 and 11 of pages 2, 3 and 4 of this Schedule, which are incorporated by reference herein.

    As of November 14, 2024, the Fund beneficially owns 4,585,532 shares of the issuer’s common stock.

    The securities reported on this Schedule as beneficially owned by TCM (the “Securities”) are held by and for the benefit of the Fund. Under the definition of “beneficial ownership” in Rule 13d-3 under the Act, it is also possible that the individual general partners, executive officers, and members of the foregoing entities might be deemed the “beneficial owners” of some or all of the Securities insofar as they may be deemed to share the power to direct the voting or disposition of such Securities. TCM, as the investment manager and general partner of the Fund, and Collin McBirney, as the member-manager of TCM, may, therefore, be deemed to beneficially own the Securities held by the Fund for the purposes of Rule 13d-3 under the Act insofar as they may be deemed to have the power to direct the voting or disposition of those Securities.

    Neither the filing of this Schedule nor any of its contents shall be deemed to constitute an admission that any of TCM or Mr. McBirney is, for any other purpose, the beneficial owner of any of the Securities held by the Fund, and each of TCM and Mr. McBirney expressly disclaims beneficial ownership as to the Securities held by the Fund, except to the extent of its or his pecuniary interests therein.

     

    5


    The calculation of percentage of beneficial ownership in Row 11 of pages 2, 3 and 4 of this Schedule was derived from the issuer’s Form 10-Q Quarterly Report filed with the Securities and Exchange Commission on August 7, 2024, in which the issuer stated that the number of shares of its common stock outstanding as of August 7, 2024 was 45,855,328 shares.

     

    6


    Item 5.

    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable.

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

    7


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: November 14, 2024

     

    TOPLINE CAPITAL MANAGEMENT, LLC
    By:   /s/ Collin McBirney
     

    Collin McBirney

    Managing Member

    TOPLINE CAPITAL PARTNERS, LP

    By:

     

    Topline Capital Management, LLC,

    its general partner

    By:   /s/ Collin McBirney
     

    Collin McBirney

    Managing Member

    COLLIN MCBIRNEY
    /s/ Collin McBirney

     

    8


    EXHIBIT LIST

     

    Exhibit A    Joint Filing Undertaking

     

    Get the next $KRMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KRMD

    DatePrice TargetRatingAnalyst
    2/14/2025$4.50Overweight → Neutral
    Piper Sandler
    7/25/2024$4.00Buy
    B. Riley Securities
    9/7/2023$4.00Buy
    Lake Street
    9/7/2023$4.50Buy
    B. Riley Securities
    11/10/2022$3.00 → $4.00Hold → Buy
    Canaccord Genuity
    11/10/2022$3.00 → $3.50Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $KRMD
    SEC Filings

    View All

    SEC Form S-8 filed by KORU Medical Systems Inc.

    S-8 - KORU Medical Systems, Inc. (0000704440) (Filer)

    8/12/25 6:54:59 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by KORU Medical Systems Inc.

    10-Q - KORU Medical Systems, Inc. (0000704440) (Filer)

    8/6/25 4:11:41 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - KORU Medical Systems, Inc. (0000704440) (Filer)

    8/6/25 4:08:43 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KORU Medical Systems downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded KORU Medical Systems from Overweight to Neutral and set a new price target of $4.50

    2/14/25 8:08:51 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    B. Riley Securities resumed coverage on KORU Medical Systems with a new price target

    B. Riley Securities resumed coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00

    7/25/24 8:28:49 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on KORU Medical Systems with a new price target

    Lake Street initiated coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00

    9/7/23 9:12:10 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $KRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    KORU Medical Systems Announces Q2 2025 Financial Results, Including Record Double-digit Revenue, and Raises 2025 Revenue Guidance

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2025. Financial Highlights •   Second quarter 2025 net revenues of $10.2 million, a 21% increase over the prior year period       •   Core business (Domestic and International) net revenues of $9.3 million, a 19% increase over the prior year period       •   Pharma Services and Clinical Trials (PST) net revenues of $0.9 mi

    8/6/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025. Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300

    8/1/25 4:55:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems to Participate in the Canaccord Genuity 45th Annual Growth Conference

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on August 13th, 2025. KORU Medical's management is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 10:30 am ET. Interested parties can access the live and archived webcast on the News/Events page of the Investors section of KORU Medical's website at www.korumedical.com. About KORU

    7/30/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by President and CEO Tharby Linda M

    4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

    8/11/25 4:26:24 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Operating Officer Pazdan Christopher

    4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

    8/11/25 4:25:19 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Adams Thomas Edward

    4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

    8/11/25 4:24:02 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Manko Joseph M. Jr. bought $349,999 worth of shares (145,833 units at $2.40) and sold $349,999 worth of shares (145,833 units at $2.40) (SEC Form 4)

    4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

    12/15/23 4:05:24 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Leadership Updates

    Live Leadership Updates

    View All

    KORU Medical Systems Appoints Adam Kalbermatten as Chief Commercial Officer

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Adam Kalbermatten as Chief Commercial Officer, effective July 28, 2025. Adam brings over two decades of commercial leadership experience in the medical device and pharmaceutical industries, with a proven track record of scaling businesses, building high-performing teams, and delivering customer-focused innovation. As Chief Commercial Officer, he will oversee all aspe

    7/7/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems to Join Russell 3000® and Russell 2000® Indexes

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025, according to a preliminary list of additions posted Friday, June 6, 2025. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by tot

    6/11/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023. Ken brings over 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing strategy, international expansion, and driving sustainable growth and profitability. As Chief Commercial Officer, Ken will have oversight of the global commercial functio

    11/8/23 4:08:00 PM ET
    $BDX
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by KORU Medical Systems Inc.

    SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)

    11/14/24 7:00:30 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by KORU Medical Systems Inc.

    SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)

    11/13/24 4:23:54 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by KORU Medical Systems Inc.

    SC 13G - KORU Medical Systems, Inc. (0000704440) (Subject)

    5/23/24 7:00:28 AM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    $KRMD
    Financials

    Live finance-specific insights

    View All

    KORU Medical Systems Announces Q2 2025 Financial Results, Including Record Double-digit Revenue, and Raises 2025 Revenue Guidance

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2025. Financial Highlights •   Second quarter 2025 net revenues of $10.2 million, a 21% increase over the prior year period       •   Core business (Domestic and International) net revenues of $9.3 million, a 19% increase over the prior year period       •   Pharma Services and Clinical Trials (PST) net revenues of $0.9 mi

    8/6/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems to Report Second Quarter 2025 Financial Results on August 6, 2025

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report second quarter 2025 financial results on Wednesday, August 6, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for internationa

    7/16/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care

    KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights First quarter 2025 net revenues of $9.6 million, an 18% increase over the prior year period Core business (Domestic and International) net revenues of $9.4 million, a 21% increase over the prior year period Gross profit of $6.0 million, a 19% increase over the prior year period, and gross margin of 62.8%, a 50-basis point improvement over th

    5/7/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care